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TherapeuticsWhen HIV was initially discovered as the causative agent of AIDS, many expected to ﬁnd a vaccine within a few
years. This has however proven to be elusive; it has been approximately 30 years since HIV was ﬁrst discovered,
and a suitable vaccine is still not in effect. In 2009, a paper published by Hutter et al. reported on a bonemarrow
transplant performed on an HIV positive individual using stem cells that were derived from a donor who was
homozygous for a mutation in the CCR5 gene known as CCR5 delta-32 (Δ32) (Hütter et al., 2009). The HIV pos-
itive individual became HIV negative and remained free of viral detection after transplantation despite having
halted anti-retroviral (ARV) treatment. This review will focus on CCR5 as a key component in HIV immunity
and will discuss the role of CCR5 in the control of HIV infection.
© 2013 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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The ﬁrst chemokine was discovered in 1977 (Walz et al., 1977) and
since then a large super family of chemokines has been identiﬁed.
Chemokines are small proteins with several functions including
immune surveillance and immune cell recruitment. The effects of
these chemokines are mediated by their G-protein-coupled receptors
(GPCR's). Chemokines are classiﬁed as C, CC, CXC and CX3C depending
on the structure and number of cysteine residues. Moreover, the recep-
tors are designated with an addition of ‘R’ to indicate receptor (Murphy
et al., 2000).pen access article under the CC BY-NC-ND license
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amino and carboxyl termini (Horuk, 1994). The C-C receptors often
share a signiﬁcant degree of homology, with ‘C-C chemokine receptor
type ﬁve’ (CCR5) and ‘C-C chemokine receptor type two’ (CCR2) sharing
75% homology (Combadiere et al., 1996). Despite the close structure of
these receptors, they bind to different ligands and mediate a variety of
effects.
The chemokine receptor CCR5 is expressed on various cell populations
includingmacrophages, dendritic cells andmemory T cells in the immune
system; endothelium, epithelium, vascular smooth muscle and ﬁbro-
blasts; and microglia, neurons, and astrocytes in the central nervous sys-
tem (Rottman et al., 1997). Natural ligands for the receptor include
‘macrophage inﬂammatory protein one alpha’ (MIP1-α) (Nibbs et al.,
1999), ‘macrophage inﬂammatory protein one beta’ (MIP1-β), ‘regulated
upon activation, normal T-cell expressed, and secreted’ (RANTES) and
‘monocyte chemotactic protein two’ (MCP-2) (Combadiere et al., 1996;
Raport et al., 1996; Samson et al., 1996a; Gong et al., 1998). The receptor
plays a role in the inﬂammatory response by directing cells to sites ofFig. 1. A. Structure of a mature HIV virioinﬂammation. Other chemokine receptors work together with CCR5 to
stimulate T-cell functions (Contento et al., 2008). The receptors enhance
T-cell co-stimulation and cytokine release from CD4+ T-cells. Further-
more, ligands for CCR5 augment the activation of T-cell responses and en-
hance the production of antigen speciﬁc T-cells (Taub et al., 1996).
During inﬂammation, the level of CCR5 expression is up-regulated in
CD8+ cells, which allows the cells to move towards sites of CD4+
T-cell and dendritic interactions (Castellino et al., 2006). This increases
the chance of CD8+cells encountering antigen speciﬁc cells. Thus, CCR5
enhances the adaptive immune response.
In 1996, it was discovered that CCR5 is necessary as a co-receptor for
entry of the macrophage tropic HIV strains (Dragic et al., 1996; Deng et
al., 1996). Dragic et al. demonstrated that the ligands for CCR5 inhibit
viral entry and envelope mediated fusion (Dragic et al., 1996). The
virus uses CCR5 especially during initial infection, whereas the alterna-
tive co-receptor ‘C-X-C chemokine receptor type four’ (CXCR4) is used
much later in HIV infection when the infected individual is progressing
towards AIDS.n. B. Structure of the HIV genome.
Fig. 2. Diagram illustrating HIV replication. (A) The virus glycoprotein receptors bind to host cell CD4 and a co-receptor CCR5. (B) Fusion of the virus with the host cell membrane
results in viral uncoating and the release of the viral nucleocapsid into the cytoplasm. (C) The enzyme reverse transcriptase converts the single stranded RNA into double stranded
DNA. (D) The viral DNA is transported to the host nucleus where it is integrated into the host's DNA. (E) Viral DNA is transcribed and translated using host cell machinery and then
cleaved by viral protease into functional viral proteins. (F) Viral RNA and proteins assemble at the cell surface and bud off the cellular membrane.
5F. Barmania, M.S. Pepper / Applied & Translational Genomics 2 (2013) 3–162. HIV replication
Replication of HIV requires entry into a host cell where it uses the
host cell machinery to propagate. The virus consists of a lipid bilayer
that contains two glycoprotein receptors, gp120 and gp41 (designated
gp160), which are used to gain entry into the host cell (Greene, 1997;
Phillips, 1996) (Fig. 1A). The viral core contains the p17matrix protein,
p24 capsid protein and the p6 and p7 nucleocapsid proteins. Thematrix
protein is found beneath the lipid bilayer where it maintains the struc-
tural integrity of the virion (Wu et al., 2004). The capsid protein forms
a protective case around the genomic material. The nucleocapsid
protein, p7, is involved in forming and stabilizing the RNA as well as
in nucleocapsid assembly (Goel et al., 2002). The p6 nucleocapsid
protein is involved in viral assembly and budding of the virus from
the host cell (Sandefur et al., 2000). The core also consists of enzymes
required for viral replication such as reverse transcriptase, integrase
and protease (Geleziunas and Greene, 1999). The viral genome is
made up of nine genes: gag (group speciﬁc antigen), pol (polymerase),
env (envelope), tat (trans-activation of transcription), rev (regulator
of virion), nef (negative factor), vpr (viral protein r), vif (viral infectivity
factor), and vpu (viral protein u) (Fig. 1B). The gag gene codes for
proteins that make up the core, while the env- and pol genes code
for gp160 and enzymes, respectively. The remaining (tat, rev, nef,
vpr, vif, vpu) genes are involved in accessory functions that aid viral
production and spread (Hirsch and Curran, 1990; Montagnier and
Clavel, 1994).
Viral replication beginswith attachment of the virus's gp120 surface
protein to the host cell CD4 receptor (McDougal et al., 1986) (Fig. 2).
This triggers a conformational change in the virus's structure, which
reveals the gp41 surface protein (Rizzuto et al., 1998). The latter willbind to a chemokine co-receptor on the host cell being either CCR5
(Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996; Dragic et al.,
1996; Doranz et al., 1996) or CXCR4 (Feng et al., 1996). Viruses that
bind to CCR5 and CXCR4 are designated R5 and X4, respectively, while
viruses that bind to both CCR5 and CXCR4 are designated R5X4.
Co-receptor binding brings the virus into close contact with the host
cell membrane as gp41 forms pores in the membrane (Srinivas et al.,
1992; Miller et al., 1993). This anchors gp120, and facilitates fusion
and entry (Helseth et al., 1991).
Cellular factors as well as p17, Vif and Nef from the virus are
involved in viral uncoating which unveils the RNA (Hirsch and Curran,
1990; Harrich and Hooker, 2002). The RNA is transcribed into double
stranded complementary DNA (cDNA) by the enzyme reverse tran-
scriptase (Varmas, 1988). The doubled stranded DNA is then incorpo-
rated into a pre-integration complex (Farnet and Haseltine, 1991),
which is transported across the nucleopore into the nucleus by the
Vpr protein (Popov et al., 1998). The integrase enzyme inserts the
DNA into the host chromosome (Varmas, 1988). After integration, tran-
scription is stimulated by host cellular RNA polymerase to produce Nef,
Rev and Tat. The latter is involved in promoting the transcription of fur-
ther HIV products by binding to promoter regions of the gene and addi-
tional host factors. The Rev product binds to transporter regions of the
gene transcripts and facilitates the movement of these messenger
RNA (mRNA) products to the cytoplasm for translation into protein
(Pollard and Malim, 1998). The Env protein product, gp160, undergoes
posttranslational modiﬁcation in the endoplasmic reticulum and then
inserts into the cell membrane. The Gag and Pol polyprotein products
assemble with the envelope proteins where budding occurs. The pro-
cess of budding triggers the catalytic activity of the protease enzyme.
The enzyme cleaves the Gag and Pol polyproteins into its constituent
Fig. 3. CCR5 protein structure. Protein structure of CCR5 indicating regions of importance with the dotted line showing disulﬁde linkage, the boxed S and P indicating sulfate and
phosphate moieties and the three zig zag lines showing palmitoylation of C moieties. The DRYLAVVH sequence is highlighted in blue. Image adapted from Blanpain and Parmentier,
2000.
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(Sierra et al., 2005)].
3. CCR5 protein structure
The CCR5 protein consists of 352 amino acids with a molecular
weight of 40.6 kDa (Samson et al., 1996a). The protein contains an
amino terminal (N-terminal), seven trans-membrane domains (TMD)
made up of hydrophobic residues, three extracellular loops (ECL),
three intracellular loops (ICL) and a cytoplasmic or carboxyl tail
(C-terminal tail). The protein is composed of conserved residues, specif-
ic motifs of charged or hydrophobic regions and post-translational
modiﬁcations. These regions are important for chemokine ligand bind-
ing, functional response of the receptor, and HIV co-receptor activity
(Fig. 3).
The N-terminal is rich in tyrosine and acidic amino acids that play an
important role in both R5 HIV interaction and chemokine binding
(Dragic et al., 1998; Rabut et al., 1998; Farzan et al., 1999). Blanpain et
al. used deletion and mutagenesis techniques in this region and discov-
ered the role of these amino acids in the N-terminal (Blanpain et al.,
1999a). Mutants lacking amino acids 2–13 responded weakly to elevat-
ed concentrations of ligands. In addition, co-receptor function was
reduced by 80%. Using alanine-scanning mutagenesis, ﬁve amino acid
positions (2, 3, 10, 11 and 18) were deemed to be important for ligand
and HIV envelope binding afﬁnity.
Similar to other chemokine receptors, cysteine residues are found
in all three ECLs and the N-terminal (Blanpain et al., 1999b). The sec-
ond ICL has a conserved sequence motif, DRYLAVVA, and a short third
ICL containing charged amino acids (Opperman, 2004). A motif desig-
nated TxP, with x referring to any amino acid, was found in the second
TMD creating a structural constraint important for receptor function
(Govaerts et al., 2001). The proline and threonine residues in this region
provide ﬂexibility to the receptor backbone. Mutation in this areareduces ligand binding and severely affects the functional response of
the receptor.
Most GPCRs have a conserved disulﬁde bond between the ﬁrst and
second ECLs (Fraser, 1989; Dohlman et al., 1990; Savarese et al., 1992;
Perlman et al., 1995). Chemokine receptors contain an additional disul-
ﬁde bond between the N-terminal and third ECL (Baggiolini et al.,
1997). These disulﬁde bonds are important for ligand binding and sta-
ble receptor conformation (Perlman et al., 1995). Naturally occurring
mutations were found at these positions in long-term non-progressors
(Carrington et al., 1999) which led to the study conducted by Blanpain
et al. (1999b) on these cysteine residues. Substitution of alanine at any
individual cysteine reduced cell surface expression of CCR5 between 40
and 70%. The cysteine mutants did not respond to CCR5 agonists, but
allowed R5 HIV infection albeit at decreased levels.
As mentioned previously, the tyrosine and acidic residues in the
N-terminal are important in HIV infection and chemokine binding.
The tyrosines are post translationally modiﬁed by sulfation, which
increases the net negative charge of the N-terminal region, facilitating
interaction with ligands and HIV (Farzan et al., 1999). Viral gp120 has
been shown to bind sulfatedmoieties on the cell surface (Mondor et al.,
1998; Roderiquez et al., 1995) and sulfated compounds can inhibit
in vitro HIV infection by binding to gp120 (Yang et al., 1996). Farzan
et al. showed that prevention of tyrosine sulfation reduced ligand and
gp120 binding afﬁnity but did not affect CCR5 expression (Farzan
et al., 1999). The serine residue at position six in the N-terminal also
contains an O-linked glycosylation modiﬁcation that affects CCR5
chemokine binding (Bannert et al., 2001).
The C-terminal region of CCR5 consists of various modiﬁcations
and residues, which affect expression and function of CCR5. Using
green ﬂuorescent fusion proteins and immunoﬂuorescence, Blanpain
et al. demonstrated that CCR5 is palmitoylated at the C-terminal. Cys-
teine residues (positions 321, 323 and 324) are acylated and serve as
an anchor between the C-terminal and the cell membrane (Blanpain et
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interaction between the receptor and signaling pathways and is
involved in receptor-mediated endocytosis (Blanpain et al., 2001;
Percherancier et al., 2001; Kraft et al., 2001). Eliminating palmitoylation
reduced surface expression by intracellular trapping of the receptor in
organelles and subsequent degradation. This reduces the amount of
receptor utilized by HIV for entry. Escape mutants that reach the cell
surface have impaired signaling but still maintain intact co-receptor
function (Blanpain et al., 2001). The C-terminal region is also enriched
in serines and threonines that provide phosphorylation sites for
G-protein coupled receptor kinases (Oppermann et al., 1999).
Thus, amino acid modiﬁcations of CCR5 have important conse-
quences for HIV infection and ligand binding afﬁnity.
4. CCR5 expression and HIV
The density of CD4 receptors on the cell surface is an important fac-
tor for HIV infection, although peripheral blood CD4+ cells have been
reported to have a relatively consistent density on the cell membrane
(Kabat et al., 1994; Poncelet et al., 1991). Nonetheless, Moore et al.
found that CCR5 expression displays large inter-individual variability
(Moore, 1997). This was shown to affect HIV infectability in vitro in
cell lines (Platt et al., 1998), macrophages (Tuttle et al., 1998) and lym-
phocytes (Wu et al., 1997).
In individuals infected with HIV, the percentage of CD4+CCR5+
T-cells is higher (13.2%) thanwhen compared to uninfected individuals
(6.2%) (Ostrowski et al., 1998). The highest percentage of expression
was found in an individual with acute HIV syndrome, recorded at
around 30–40%. The variation in CCR5 percentages in HIV infected indi-
viduals did not correlate with genotype as three individuals with het-
erozygosity for Δ32, a CCR5 mutation known to reduce HIV infection
(reviewed in Section 7), had different levels of expression (2.7%, 13.1%
and 17%). In contrast, the activation state of the CD4+ cells asmeasured
by HLA-DR positively correlated with CCR5 expression.
In 1999, a study conducted by de Roda Husman et al. assessed CCR5
expression in terms of CCR5 genotype and HIV infection and progres-
sion (de Roda Husman et al., 1999). Individuals with wild-type CCR5
receptors had higher levels of CD4+CCR5+ T-cells than those with het-
erozygous Δ32 genotypes, and this was observed in both HIV infected
(wild-type — 28%; Δ32 heterozygote — 21%) and uninfected
individuals (wild-type — 15%; Δ32 heterozygote — 10%). Furthermore,
infected individuals in end stage HIV progression had higher percent-
ages than individuals that had not progressed. The study postulated
that the CD4+CCR5+ T-cell percentage is directly correlated with HIV
disease progression due to the constant immune activation associated
with HIV. The presence of the CCR5 receptor on memory effector
T-cells (Mo et al., 1998) or mature activated T-cells supports the latter
ﬁnding.
Reynes et al. postulated that CCR5 expression affects virus produc-
tion and viral load (Reynes et al., 2000). The study found a strong corre-
lation between CCR5 density and viral load, but a weak correlation
between CD4+CCR5+ T-cell percentage and viral load. In addition, cell
activation did not affect CCR5 density and there was no correlation
between cell activation state and viral load. Infection with HIV did not
up-regulate CCR5 density, as therewas little difference between density
in infected and uninfected individuals. Furthermore, treatment of
infected individuals with anti-retroviral drugs (ARVs) reduced viral
load but not CCR5 density. As such, the strong correlation between
viral load and CCR5 density was independent of activation state or
up-regulation of CCR5 by HIV. Platt et al. elucidated a threshold of
10,000 CCR5molecules per CD4+ cell as a requirement for HIV infection
(Platt et al., 1998). Levels below this threshold value showed a marked
reduction in cell infectability. Most individuals with a low viral load
have CCR5 densities below this value (Reynes et al., 2000). Thus, the
in vivo importance of CCR5 density in determining viral load was
established.5. Regulation of CCR5 expression
CCR5 expression is regulated at three levels: (1) genetic factors
(reviewed in Section 8); (2) factors involved in activation, signaling
and trafﬁcking of the receptor including desensitization (the recep-
tor stops responding to stimulus), internalization (receptors are re-
moved from the cell surface after stimulus and move to intracellular
organelles) and recycling (receptors return to the cell surface) and;
(3) environmental or other triggers.
Chemokine receptor CCR5 is part of the GPCR family, which upon
binding to the relevant ligand results in the release of the αi and βγ
G-protein subunits. This in turn mediates an effector response
(Aramori et al., 1997; Zhao et al., 1998). These responses include
the release of adenylyl cyclase and phospholipase Cβ, which release
intracellular calcium and form inositol triphosphate. These products
activate phosphorylation of the receptor via protein kinase C and
G-protein coupled receptor kinases (GRK) (Oppermann et al., 1999).
Phosphorylation via these kinases occurs at the serine and
C-terminal residues of CCR5. Binding of β-arrestin 1 and 2, which
are regulatory proteins, occurs at the activated serines (Kraft et al.,
2001) and the conserved DRY motif in the ICL (Gosling et al., 1997).
The β-arrestin proteins desensitize the receptor to further stimulation
but also participate in receptor-mediated endocytosis (Huttenrauch
et al., 2002).
The level of CCR5 expression is determined by the rates of endocyto-
sis and recycling. Theβ-arrestin protein facilitates the former process by
participating in the binding process between the phosphorylated recep-
tor and clathrin coated pits (Goodman et al., 1996; Laporte et al., 1999).
An alternative pathway of endocytosis can occur by cholesterol rich
caveolae dependent pathways (Mueller et al., 2001). Once endocytosis
is complete, the phosphorylated receptor collects in perinucleur
endosomes. These endosomes then return the receptor to the cell sur-
face in a dephosphorylated form (Signoret et al., 1998; Pollok-Kopp
et al., 2003). According to Signoret et al. the receptor is not subject to
degradation pathways, as it does not accumulate in late endosomes
(Signoret et al., 1998). Infection and entry of HIV into cells does not
require CCR5 internalization or signaling (Gosling et al., 1997), but the
chemokine-induced endocytosis decreases available receptor for HIV
use (Amara et al., 1997; Mack et al., 1998). This is the mechanism of
chemokine mediated anti-HIV activity.
Environmental factors, affecting CCR5 expression, include infectious
agents such as Mycobacterium tuberculosis (MTb) and HIV. Santucci
et al. showed that MTb infection up-regulates CCR5 expression thereby
facilitating HIV cell infectability (Santucci et al., 2004). Endotoxins such
as lipopolysaccharide (LPS) can also increase CCR5 expression
(Juffermans et al., 2001). The latter study injected LPS into HIV negative
males to induce endotoxemia; this resulted in a 2–4 fold increase of
CCR5 on CD4+ T-cells. Studies in vitro yielded similar results with LPS,
MTb and Staphylococcus aureus, demonstrating that bacterial infection
can aid HIV viral entry by up-regulating CCR5. Shalekoff et al. analyzed
the effect of TB and HIV infection in leukocyte populations in vivo
(Shalekoff et al., 2001). The study found that CCR5 expression was
signiﬁcantly increased in all leukocyte subsets during TB, HIV and dual
infection. However, the level of CCR5 expression on CD4+ cells was
not increased.
Conversely, Ostrowski et al. showed that HIV affects the level of
expression of CCR5, as there is a direct correlation with HIV disease
progression (Ostrowski et al., 1998). Individuals with end stage HIV
were shown to have the highest percentages of CCR5 expressing
CD4+ cells.
Clerici et al. found that immune activation in Africa is environmen-
tally induced and is not due to genetic determinants (Clerici et al.,
2000). This results in an up-regulation of CCR5mRNA and concomitant-
ly CCR5 cell surface expression, increasing R5 HIV infection.
Other factors affecting expression include drugs such as statins
that have been shown to reduce the level of CCR5 mRNA and increase
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both R5 and X4 HIV infection in vitro. Perney et al. studied the effect of
chronic alcohol consumption on CCR5, since the receptor is involved
in inﬂammatory reactions (Perney et al., 2004). The study showed
that in comparison to control subjects, alcoholic individuals had
lower CCR5 densities on CD4+ T-cells.
Cytokine levels are also known to affect CCR5. Cytokines affect CCR5
expression with pro-inﬂammatory cytokines such as interleukin 2
(IL-2) (Wu et al., 1997; Bleul et al., 1997), interleukin 12 (IL-12),
tumor necrosis factor α and INF-γ increasing CCR5 expression on
peripheral blood mononuclear cells (Hariharan et al., 1999; Patterson
et al., 1999). The anti-inﬂammatory cytokine, interleukin 10 (IL-10),
also increased CCR5 density on monocytes by prolonging the half-life
of CCR5 mRNA (Sozzani et al., 1998).
6. CCR5 gene structure
OnMarch 19 1996, Samson et al. published theﬁrst report indicating
the molecular cloning, expression and ligand binding properties of
CCR5 (Samson et al., 1996a). Four months later, two separate reports
conﬁrming these ﬁndings were published (Combadiere et al., 1996;
Raport et al., 1996). Samson et al. cloned and expressed theﬁfth chemo-
kine receptor, designated Chem13 (Samson et al., 1996a). Using a mu-
rine clone they examined a human genomic DNA library, isolated, and
puriﬁed a positive clone, which was physically linked with the already
discovered CCR2 gene. The ORFs of these two genes were separated
by 17.5 kb. The similarity between CCR2B and CCR5 was found to be
71% identical in amino acid residues and 55%, 49% and 48% identical in
residues to CCR1, CCR3 and CCR4, respectively (Raport et al., 1996).
Combadiere et al. (Combadiere et al., 1996) isolated a human CCR5
clone, identical to the clone identiﬁed in the Samson paper (Samson
et al., 1996a), which differed at position 90 of the protein with
leucine substituting for alanine. This ﬁnding illustrated that these two
sequences are different alleles of the CCR5 gene with a novel variant
having been discovered. Additionally, Combadiere et al. demonstrated
that the signal transduction pathway is petussis toxin sensitive,
conﬁrming its nature as a GPCR (Combadiere et al., 1996).
The CCR5 gene was localized to chromosome 3p21 (Liu et al.,
1996) and was found within a cluster of genes encoding for other
chemokine receptors which included CCR1, CCR2, CCR3, XCR1 and
CCBP2 (Samson et al., 1996a; Maho et al., 1999). The CCR5 gene is
composed of three exons, two introns and two promoters (Fig. 4)
(Mummidi et al., 1997). The upstream promoter, designated Pu or
PR2, consists of a 1.9 kb region preceding exon 1 that is 57 bp in
length. Exon 1, the start of the coding region, is followed by the ﬁrst
intron that is 501 bp in length. Exon 2 is intronless and can be
found as exon 2a (235 bp) and exon 2b (54 bp). The second promoter,
designated Pd or PR1, encompasses the intron 1 and exon 2 regions
(Mummidi et al., 2007). A 1.9 kb intron is located between exon 2 and
exon 3. Exon 3 is intronless and contains the entire ORF of the CCR5
gene, 11 bp of the 5′ UTR and the complete 3′ UTR (Mummidi et al.,
1997).
The CCR5 gene has several ATG transcription sites, prior to the
start codon of exon 3, leading to the generation of different CCR5
transcripts, which vary in their 5′ UTR regions (Mummidi et al., 1997).
These transcription start sites are usually negated by stop codonsFig. 4. Structure ofpreceding exon 3, with the longest resulting cistrons being 9 and 15
amino acids long. The formation of multiple transcripts upstream of
exon 3 is a potential regulator of CCR5, through reduction of protein
expression. The CCR5 protein containing transcripts are referred to as
CCR5A and CCR5B. These two transcripts code for the same CCR5
protein with CCR5B lacking the 235 bp exon 2b fragment.
The two promoters for CCR5, Pu and Pd, contain sequences with
high proportions of pyrimidines, which is unusual for promoters,
and lack the canonical TATA and CCAAT sequences (Mummidi et al.,
1997). However, the Pd promoter consists of a non-consensus TATA
box. Furthermore, the upstream or Pu promoter was found to be
weaker than the downstream or Pd promoter with the latter having
up to ﬁve fold greater activity (Liu et al., 1998). Liu et al. characterized
the transcriptional activity of the Pd promoter, which contained two
TATA motifs as well as a myriad of transcription factor binding sites
(Liu et al., 1998). Negative regulatory factors were found in intron 2
and the region upstream of the Pd promoter. The use of two promoters
result in different CCR5 transcripts with transcription occurring at
multiple start sites found in either exon 1 or exon 2 (Mummidi et al.,
1997, 2007).
Transcription of the CCR5 gene driven by the Pu promoter contains
exon 1, and results in CCR5A or B (Mummidi et al., 2007). Alternatively,
transcription driven by the Pd promoter results in truncated isoforms,
which are not individually named. Contrary to previously established
data that suggested the Pu promoter was less transcriptionally active
and therefore not an important determinant in CCR5 gene expression,
Mummidi et al. showed that this was an error (Mummidi et al., 2007).
Using RT-PCR based methods, the group identiﬁed Pd as the promoter
used in unstimulated primary T-cells, whereas Pu was initially used in
stimulated T-cells. The erroneous data was a result of transformed
T-cells being used in experimentation, thereby affecting the level of
CCR5 protein expression via the Pu promoter.
The promoter regions include various sites for transcription factor
binding, which according to Bream et al. can produce various CCR5
promoter alleles that affect CCR5 expression (Bream et al., 1999).
Mummidi et al. found binding sites for activator protein one, octamer
one (Oct-1) and GATA transcription factors on the CCR5 gene
(Mummidi et al., 1997). In addition,Moriuchi et al. found 11 designated
areas deemed to be protected from DNase digestion (Moriuchi et al.,
1997). The areas consisted of sequences resembling transcription factor
binding sites. Later the group discovered that one of the DNase
protected areas contained a third GATA binding site (Moriuchi et al.,
1999). Furthermore, the group found that one of the binding sites for
GATA, designated GATA-1, up-regulated CCR5 promoter activity and
that mutation of the binding site signiﬁcantly reduced transcriptional
activity. In the Pd promoter, Liu et al. found a myriad of transcription
factor binding sites, with nuclear factor-kappa-beta being an effective
stimulator of the CCR5 promoter (Liu et al., 1998).
The transcription factor Oct-1 was found to negatively regulate the
Pu promoter. Octamer two (Oct-2), however, was found to actively
stimulate the promoter (Mummidi et al., 2007). The Oct transcription
factors have been shown to up-regulate CCR5 protein expression and
increase fusion with R5 HIV (Moriuchi and Moriuchi, 2001). Rosati
et al. identiﬁed multiple binding sites for ‘CCAAT/enhancer-binding
protein beta’ (CEBPβ) within the CCR5 gene, mainly in the intron and
promoter (Rosati et al., 2001). Moreover, they found that an increasethe CCR5 gene.
Fig. 5. Diagram of the differences between wild-type CCR5 and Δ32. Illustration of the region involving the Δ32 mutation with the upper section showing the translation of the wild
type CCR5 protein while the lower section demonstrates the translation of the mutant protein. The red highlighted region in the wild type sequence refers to the region deleted in
Δ32. The red highlighted region in the mutant protein sequence refers to the novel amino acids inserted followed by the stop codon.
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lymphoid and myeloid cell lineages, CEBPβ binds to sites in the intron.
Meanwhile, promoter-binding sites were found in speciﬁc cell types
in the myeloid lineage. The importance of CEBPβ was indicated by the
high levels of the factor in HIV positive individual blood cells. Further-
more, these individuals had higher levels of CCR5 positive lymphocytes.
Rosati et al. (2001) further supported the study conducted by Liu et al.
(1998), in which a negatively regulating sequence was found in the
intronic region, emphasizing the importance of intronic regions in
CCR5 expression.
The regulation of CCR5 and its effect on protein expression at the
level of the cell membrane is complex. The introns as well as sequences
in the 5′ and 3′ UTR have been found to affect CCR5 gene regulation
(Mummidi et al., 1997). As such, mutations in these regions should be
considered important in regulation.
7. The CCR5Δ32 mutation
The CCR5Δ32mutation was initially discovered in 1996 (Dean et al.,
1996; Liu et al., 1996; Samson et al., 1996b) as a genetic mutation that
confers protection to cells from infection by HIV. Genetic analysis of
the open reading frame (ORF) of the gene by Liu et al. revealed a dele-
tion of 32 basepairs consisting of nucleotides 794 to 825 (Liu et al.,
1996). The deletion involves a frameshift mutation with the inclusion
of seven novel amino acids following amino acid 174 and a stop
codon at amino acid 182 (Fig. 5). The mutant allele contains 215
amino acids in comparison to the full-length 352 amino acid wild type
CCR5. Samson et al. found that the region affectedwas the second extra-
cellular loop (Samson et al., 1996b). The subsequent protein lacked the
last three transmembrane domains as well as regions important in
G-protein interaction and signal transduction. Both groups discovered
that CD4+ cells with themutated CCR5 prevented HIV envelope fusion.
The Δ32mutant allele is conﬁned mostly to individuals of European
descent, at gene frequencies of approximately 10%, and has a north to
south latitude decline in frequency (Martinson et al., 1997). Martinson
et al. analyzed the distribution of the Δ32 mutation in more than 3000
individuals from various countries and found a 2–5% gene frequency
in Europe, Middle East and some parts of the Indian subcontinent
(Martinson et al., 1997). Isolated incidences of Δ32 found in other re-
gions were attributed to European gene ﬂows into these areas. The
highest frequency of the mutation was discovered in the Ashkenazi
Jewish population at frequencies of 20.93%. In 2005, Novembre et al.
conﬁrmed these results when they assessed the Δ32 frequency in vari-
ous population groups worldwide (Novembre et al., 2005). The mutant
allele is absent in Black populations excluding the African American
group which may have acquired the mutation through admixture
(Dean et al., 1996; Liu et al., 1996; Samson et al., 1996b).
The origin of the Δ32 mutant allele was dated back to between
275 and 1875 years ago, as a unique mutation that increased overthe years due to a selective pressure (Stephens et al., 1998). Stephans
et al. used haplotype analysis on the chromosomes of 192 Caucasian
individuals and estimated the origin using a coalescence theory
(Stephens et al., 1998). They hypothesized that the Black plague was
the strong selective pressure that caused the mutant allele boom.
Historical data however suggests that the Black plague is not the se-
lective force. The distribution of Δ32 in a north to south gradient does
not correspond to casualties of the plague. In fact, the distribution fol-
lows a south to north gradient (Cohen and Weaver, 2006). Moreover,
the Black plague showed the greatest casualties and effects in areas
with the lowest allele frequencies of Δ32, such as the Mediterranean
region and China. In 2004, Mecsas et al. infected CCR5 deﬁcient mice
with the bacterial pathogen known to cause the Black plague (Mecsas
et al., 2004). The experimental data demonstrated no differences in
bacteria growth or survival of the deﬁcient mice in comparison to
CCR5 containing mice. The ﬁnding of ancient DNA in skeletal remains
dating back 2900 years presents further evidence. The Δ32 allele fre-
quency found in these remains was similar to that found in individuals
ridden by the plague in the same region (Hummel et al., 2005).
Smallpox was another pandemic deemed culpable for the Δ32 mu-
tant allele increase (Galvani and Slatkin, 2003). The pandemic had se-
vere casualties that exceeded those of the plague. Smallpox is a virus
similar to HIV, as poxviruses are known to infect lymphocytes using
chemokine receptors (Novembre et al., 2005). Conversely, historical
evidence refutes this theory as smallpox started outside Europe and
did not affect anyone country more signiﬁcantly than another (Cohen
and Weaver, 2006). The discovery of ancient DNA with similar allele
frequencies ofΔ32 indicated that historic pandemics such as the plague
and smallpox did not result in the allele increase.
Faulds and Horuk suggested that Δ32 arose without a selective
event (Faulds and Horuk, 1997). Tandem repeats found in the coding
region of the CCR5 gene could cause unequal homologous recombina-
tion, which results in the Δ32 allele. However, the origins of the Δ32
mutation remain an enigma.
The hype surrounding the Δ32 mutation stems from its ability to
protect homozygous individuals from HIV. However, in 1997, studies
showed that some individuals with homozygous Δ32 were infected
with HIV (Biti et al., 1997; O'Brien et al., 1997; Theodorou et al., 1997).
Analysis of the HIV strains in these individuals revealed the presence
of X4 utilizing HIV, accompanied by very rapid CD4+ T-cell decline
(Michael et al., 1998). This indicates that the mutation does not protect
Δ32 homozygous individuals from viral strains which utilize alternative
receptors.
The protective effect of the Δ32 mutation towards HIV is a conse-
quence of an inhibition of CCR5 protein expression on the cell surface.
This prevents HIV from utilizing the receptor for viral entry. In addi-
tion, the Δ32 protein, localized to the endoplasmic reticulum, exerts
a trans-dominant negative effect on the wild type CCR5 protein,
inhibiting its transport to the cell surface (Benkirane et al., 1997;
Table 1
List of previously identiﬁed mutations in the protein-coding region of the CCR5 gene.




I42Fb A124T TMD 1
L55Qb,c T164A TMD 1
R60Sb G180T ICL 1
A73Vb C218T TMD 2
C101Xd T303A ECL 1
G106Rb G316A TMD3
C178Re T532C ECL 2
S185Rb A553C ECL 2
L215Sa,c A187T TMD 5
I254Ta,b T758C TMD 6
R223Qb,c G668A ICL 3
228delKb 680del3 ICL 3
C269Fb G806T ECL 3
G301Vb G902T TMD 7
FS299c 893delC TMD 7
A335Vb,c C1004T C-terminal
Y339Fa,b,c A1016T C-terminal
Footnote: All variants (except 228delK and FS299) are named with the ﬁrst letter
indicating wild-type amino acid. The number between the wild-type amino acid and
the last letter indicates the position on the CCR5 protein, and the last letter indicates
the mutant amino acid. 228delK is a deletion of a three-nucleotide codon, which
codes for lysine at position 228 while FS299 is a frameshift caused by single basepair
deletion. “a” represents variants causing conservative amino acid changes. “b” represents
variants discovered in (Carrington et al., 1997), “c” represents variants discovered by
(Ansari-Lari et al., 1997), “d” represents variants discovered by (Quillent et al., 1998)
and “e” represents variants discovered by (Magierowska et al., 1999).
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et al. showed that the mutant protein reduces the surface expression
of wild type CCR5 and CXCR4 by dimerization (Agrawal et al., 2004).
This conferred a broad-spectrum inhibition to R5, X4 and R5X4 HIV
infection. HomozygousΔ32 individualswithmutant protein expression
in CD4+ cells were shown in vivo to have down-regulated CXCR4
surface protein expression and decreased susceptibility of the cells to
X4 infection. Thus, the Δ32 protein product is of great importance in
providing resistance to HIV infection. This was further supported by
evidence suggesting that Δ32 homozygous individuals with HIV infec-
tion do not stably express theΔ32 protein, and are devoid of themolec-
ular mechanism of protection (Agrawal et al., 2004, 2007). Stable
expression of the mutant protein can be affected by polymorphisms in
the promoter region of the gene (Jin et al., 2008). Individuals homozy-
gous for Δ32 with the 59537-A/A variant had reduced expression of
mutated protein in comparison to homozygous individuals with the
wild type 59537-G/G promoter variant.
8. CCR5 mutations
Mutations in the coding and promoter regions of the CCR5 gene
have been well documented in relation to HIV infection and progres-
sion. Coding region mutations affect the CCR5 protein structure, which
can affect production, transport, chemokine binding, signaling and
expression of the CCR5 receptor. Mutations in the promoter region
can affect the DNA transcription factor binding or regulatory sites lead-
ing to aberrations in CCR5 mRNA production.
8.1. Coding region mutations
Six of the variants in Table 1 (I12T, C20S, I42F, L55Q, A73V, and
C101X) have been previously identiﬁed in individuals with Δ32
(Carrington et al., 1997; Quillent et al., 1998).
The C101X (Quillent et al., 1998) and FS299 (Ansari-Lari et al., 1997)
variants result in premature termination of translation. The C101X
variant discovered in an HIV negative homosexual male individual,frequently exposed to HIV, results in substitution of cysteine at position
101 of the CCR5proteinwith a stop codon andhas a high allele frequency
in central Africa (Blanpain et al., 2000). Consequently, this premature
termination of translation forms a protein that contains only two trans-
membrane domains. Studies performed in vitro indicate that this protein
is not expressed on the cell surface, does not function as a HIV
co-receptor and is misfolded. The consequence of these factors is that
the protein is retained intracellularly (Blanpain et al., 2000). The FS299
variant, found at 3–4% allele frequency in Asia (Blanpain et al., 2000), is
a frameshift mutation causing absence of the latter portion of the sev-
enth TMD and complete absence of the C-terminal. Protein expression
on the cell surface is reduced because of intracellular retention. Further-
more, it does not bind or respond to chemokines but still has the ability
to bind to HIV, albeit with reduced efﬁciency (Blanpain et al., 2000).
The I12T, C20S and A29S variants are all located in the N-terminal.
According to Carrington et al., the variants markedly reduce cell
surface expression and ligand binding with the former two not func-
tioning as HIV co-receptors (Carrington et al., 1999). Conversely,
Blanpain et al. found the I12T variant mediated HIV entry (Blanpain
et al., 2000). The C20S variant prevents disulﬁde bond formation
between the N-terminal and ECL 3. Considering the importance of this
bond in chemokine binding (Blanpain et al., 1999b), the variant is
unable to function or respond to chemokines in vitro (Blanpain et al.,
2000). The variant also reduces cell surface expression but does not
prevent HIV co-receptor function. Blanpain et al. also refute the ﬁndings
of the A29S variant, as expression on the cell surface was found to be
within the normal wild-type range (Blanpain et al., 2000). However,
the variant does not respond to MIP-1α and MIP-1β but does respond
toMCP-2 and can function as anHIV co-receptor (Blanpain et al., 2000).
The I42F, L55Q, and A73V variants are found in the ﬁrst and second
TMDs, and according to Carrington et al., these variants support HIV
infection and have a ~4–8 fold higher afﬁnity for ligands (Carrington
et al., 1999). Howard et al. demonstrated that both I42F and A73V
have reduced surface expression in comparison to wild-type receptors,
with the former showing increased binding to RANTES and the latter
having decreased HIV co-receptor activity (Howard et al., 1999). The
L55Q receptor is a variant affecting a highly conserved residue, which
is important in mediating receptor activation but not chemokine
binding afﬁnity (Blanpain et al., 2000).
The C178R variant, initially discovered in the Vietnamese population
(Magierowska et al., 1999), affects a highly conserved cysteine involved
in disulﬁde bonding between ECL-1 and ECL-2, which is important for
CCR5 structure and in HIV binding (Wu et al., 1997). Studies show the
variant causes a dramatic reduction in cell surface expression with
intracellular retention of the misfolded receptor (Blanpain et al.,
2000). The mutant receptor does not bind or respond to chemokines
but can still bind HIV.
The R223Q variant is also known to affect a conserved residue.
Carrington et al. observed a decrease in variant co-receptor function
while still maintaining the ability to bind to gp120 (Carrington et al.,
1999). Analysis by Capoulade-Metay et al. found no change in CCR5
expression or chemokine binding while Zhao et al. found no effect on
HIV infection in vitro or the CCR5 mRNA level (Capoulade-Metay et al.,
2004; Zhao et al., 2005).
The G106R variant changes the residue hydrophobicity in the third
TMD, resulting in reduced surface expression (Capoulade-Metay et al.,
2004) without affecting levels of mRNA production (Zhao et al.,
2005). The variant also decreases binding to chemokines and HIV.
The S185R, I254T and C269F variants are found in the South East
Asian population group (Capoulade-Metay et al., 2004). The former
two variants may alter residue charge and hydrophobicity respectively.
The receptor function and HIV co-receptor activity, however, remain
similar to thewild-type receptor. In contrast, the C269F variant disrupts
the conserved cysteine involved in disulphide linkage of ECL-3 to the
N-terminal. This results in reduced cell surface expression, decreased
binding to MIP-1β and RANTES and weak HIV co-receptor binding.
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South Africa has one of the highest levels of HIV infection in the
world with approximately 10.6% of the South African population
being infected with HIV (Statistics South Africa). The Δ32 mutation is
found heterozygously in the Caucasian population at an allelic frequen-
cy of 9.4% but is virtually absent from the Black African population.
The C101X variant was not detected in the South African Black popula-
tion but was found at an allelic frequency of 0.7% in Caucasians
(Williamson et al., 2000).
In 2001, Peterson et al. identiﬁed seven novel variants (D2V, P35,
Y89, L107F, P162, R225X and R225Q) exclusive to the Black African
and Coloured population groups as well as six previously discovered
variants (L55Q, S75, R223Q, A335V and Y339F) (Petersen et al., 2001).
Further investigation by Hayes et al. showed that the novel P35 variant
was not signiﬁcantly different in slow versus fast progressors (Hayes
et al., 2002). The A335V variant, found homozygously in a Black African
female and heterozygously in a Coloured male and female, may have
signiﬁcantly contributed to the long-term non-progression seen in
these individuals.
In 2010, mutant receptor constructs from four novel variants
(L107F, R225Q, D2V, and R225X) identiﬁed in the Peterson paper
were analyzed in vitro for their effects on expression, chemokine
binding and response, and HIV co-receptor properties (Folefoc et al.,
2010). The D2V variant found in the N-terminal showed decreased
CCR5 expression, reduced chemokine binding and response, and
loweredHIV infection. The R225Xmutation, on the other hand, resulted
in premature termination of translation in the third cytoplasmic loop,
showed no surface expression, chemokine binding and response, and
could not support HIV infection. The latter mutation was found
heterozygously and could partially protect against HIV in these
individuals.
Studies in South Africa have focused mostly on determining Δ32
frequency and mutations in the ORF. However, in 2010 a 9.2 kb
region encompassing the entire CCR5 gene was analyzed for SNPs,
indels and haplotypes in 35 Black and 35 Caucasian individuals in
South Africa (Picton et al., 2010). The study revealed 68 SNPS, four
indels, theΔ32 mutation as well as seven complex haplotypes, while il-
lustrating that the diverse variation in the CCR5 gene in the South
African population may explain differences in response to HIV.
8.2. Promoter region mutations
A plethora of studies surrounding mutations and effects has been
completed on the ORF of the CCR5 gene. Although these mutations
signiﬁcantly inﬂuence CCR5 and HIV infection, the mutations within
the intronic, promoter and untranslated exons should also be included.
Martin et al. performed denaturing high pressure liquid chroma-
tography and single strand conﬁrmation polymorphism analysis on
HIV positive patients (Martin et al., 1998). They identiﬁed 10 SNPs
that in different combinations created four common haplotypes
(CCR5 P1–4) and six infrequent haplotypes (CCR5 P5–10). These
haplotypes affect the progression of HIV at varying rates.
A CCR2 variant, known as CCR2–64I and located in the ﬁrst TMD of
the CCR2 protein, slows the progression of HIV irrespective of Δ32
status (Smith et al., 1997; Kostrikis et al., 1998). Due to the close
proximity of CCR2 and CCR5, linkage disequilibrium between variants
in the two genesmay cause the slowprogression as the CCR2 receptor is
rarely used for HIV infection (Deng et al., 1996). A cytosine/thymine
(C/T) polymorphism at position 59653 (according to U95626) in intron
2 of the CCR5 genewas shown to be in 100% linkage disequilibriumwith
the CCR2–64I polymorphism (Kostrikis et al., 1998); however, the pro-
tection provided via linkage of the variants could not be established
(Martin et al., 1998).
An A/G polymorphism at position 59029 (GenBank Accession:
U95626) in the promoter region of CCR5 has been shown to affect HIV
progression (McDermott et al., 1998). Individuals with an A/A genotypeprogress rapidly towards AIDS in comparison to individuals with the G/
G genotype which progress 3.8 years more slowly. The latter genotype
was associated with 45% lower promoter activity (McDermott et al.,
1998). The A/A allele is found in the CCR5 P1 haplotype and has poten-
tially greater efﬁcient promoter activity, even though it is not found in
any transcription factor binding regions. Shieh et al. found that individ-
uals homozygous for the A/A genotype had higher levels of CD4+ cells
expressing CCR5 (Shieh et al., 2000). This polymorphism was shown
to determine CCR5 expression and HIV infection in vitro (Salkowitz
et al., 2003).
A study performed by de Souza et al. on the effect of four promoter
polymorphisms on HIV perinatal transmission in Brazilian children,
revealed two genotypes affecting HIV transmission (de Souza et al.,
2006). The 59353 T/T genotype was associated with an increase in
HIV transmission, while the 59402 A/A genotype has a protective
effect. Strong linkage disequilibrium between the 59029 A/A and
59353 T/T genotypes has been identiﬁed. Individuals lacking these
genotypes progress more slowly towards AIDS (Clegg et al., 2000).
Promoter variants can also affect transcription factor binding. This
was illustrated by Bream et al. who showed that certain variants
bind more efﬁciently than other variants do (Bream et al., 1999).
9. Role of CCR5 deﬁciency in disease
Individuals homozygous for the Δ32 mutation, which abolishes
CCR5 receptor expression, are healthy and at no apparent disadvantage
(112, 114). Other than its protective effect in HIV infection, the muta-
tions role in providing a protective or negative impact on other diseases
remains controversial.
In rheumatoid arthritis, CCR5+ monocytes are found in the synovial
ﬂuid (Kohem et al., 2007) as the receptor plays a role in the inﬂamma-
tory process. A meta-analysis showed that the Δ32 mutation provides
protection in the latter disease (Prahalad, 2006), as the severity of the
disease is reduced (Scheibel et al., 2008). In renal allograft outcome,
CCR5 deﬁcient mice had a signiﬁcant decrease in chronic renal trans-
plantation rejection (Dehmel et al., 2010). This favorable outcome is
due to a decrease in inﬂammatory reactions in the acute phase while
in the chronic phase the alternative macrophage pathway is activated.
During the classic macrophage pathway a strong pro-inﬂammatory
response ensues, but in the alternative pathway a wound healing or
immune-suppressive response is characterized (Martinez et al., 2009).
The Δ32 allele has also been associated with protection in coronary
artery disease and myocardial infarction (Szalai et al., 2001; Gonzalez
et al., 2001; Pai et al., 2006). The mutant allele was associated with
lower levels of triglycerides and higher HDL plasma levels, both beneﬁ-
cial in reducing the risk of cardiovascular disease (Hyde et al., 2010).
The use of the CCR5 inhibitor, maraviroc, was also associated with
better lipid proﬁles (DeJesus et al., 2008). In 2006, Henckaerts et al.
postulated that a deﬁciency of CCR5 could be protective in primary scle-
rosing cholangitis (PSC) (Henckaerts et al., 2006). Conversely, the Δ32
allele frequency was signiﬁcantly higher in PSC patients compared to
controls and furthermore the former individuals had more severe liver
disease (Eri et al., 2004).
Studies in mice show that CCR5 deﬁciency increases the severity
of brain injury in stroke (Sorce et al., 2010). Deﬁciency in CCR5 is
also associated with impaired osteoclast differentiation and osteoblast
maturation leading to defective bone repair in mice (Hoshinoa et al.,
2009). Glass et al. showed that in mice, CCR5 is essential for survival
against West Nile virus (WNV) infection (Glass et al., 2005). A further
study in humans homozygous for Δ32 illustrated a signiﬁcant correla-
tion between the mutation and fatality in WNV infection (Glass et al.,
2006). The mutation has also been implicated in severe tickborne
encephalitis symptoms (Kindberg et al., 2008) and adverse reactions
to yellow fever virus vaccine (Pulendran et al., 2008).
High levels of CCR5 are signiﬁcantly associated with non-metastatic
colorectal cancer, whereas weak or deﬁcient CCR5 expression is
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(Zimmerman et al., 2010). In bone marrow transplants, CCR5 presence
on CD4+ T-regulatory cells is important in prolonging graft survival
(Wysocki et al., 2005). This was corroborated by a study, which showed
that CCR5 genotypes with higher levels of expression have a signiﬁcant
survival outcome (McDermott et al., 2010). However, contrary to these
ﬁndings, Bogunia-Kubik et al. demonstrated thatΔ32 individuals have a
reduced likelihood of developing graft vs. host disease (Bogunia-Kubik
et al., 2006).
10. CCR5 as a target in HIV therapy
10.1. Anti-retroviral drugs and vaccines
As mentioned previously R5 viruses are predominant during initial
HIV infection whereas X4 or R5X4 viruses usually appear later in infec-
tion when the infected individual is progressing towards AIDS. Consid-
ering the role of the CCR5 receptor in HIV infection,Maraviroc (Pﬁzer), a
new class of ARVs which are small molecule CCR5 receptor antagonists
was approved in 2007.Maraviroc was indicated for use in infected indi-
viduals with R5 tropic strains who were treatment experienced
(Selzentry, 2007). Other similar CCR5 antagonists included Vicriviroc
(Schering-Plough) and Aplaviroc (GlaxoSmithKine). Small molecule
antagonists bind to CCR5 hydrophobic residues in the TMDs and
prevent the interaction of HIV with the receptor (Dragic et al., 2000;
Maeda et al., 2006, 2008).
The receptor antagonists are atypical in comparison to traditionally
used ARVs as the drug binds to host cellular factors instead of HIV
directly. However, HIV resistant variants have been discovered. Resis-
tance occurs either as a result of CXCR4 receptor usage (Westby et al.,
2006) or the ability to use drug bound CCR5 for entry (Tilton et al.,
2010). Safarian et al. proposed the use of a combination of CCR5 direct-
ed HIV therapies to synergistically inhibit HIV and slowdown the emer-
gence of resistant strains (Safarian et al., 2006).The group illustrated
that anti-CCR5 monoclonal antibodies together with small molecule
inhibitors were more effective in preventing HIV entry as a result of
the different mechanisms of action.
In 2007, a phase IIb HIV vaccine trial was conducted in various
countries including South Africa. The study aimed at increasing a
cellular immune response towards HIV in uninfected individuals.
Results from the study showed that the vaccine did not protect against
HIV infection, neither did it inhibit the progress of HIV once individuals
were infected. Alarmingly, the vaccine may have increased the suscep-
tibility of participants to HIV infection although themechanism remains
unknown (Sekaly, 2008).
Production of an HIV vaccine is fraught with many challenges
including the inability to use live or dead virus due to the risk of
infecting participants. However, there is no suitable model to investi-
gate the effects of the vaccine; humanized mouse models may alleviate
this problem. In addition, there are many HIV variants due to the rapid
mutation rate, which complicates the production of a broadly effective
vaccine (Gallo, 2010). The viral properties of HIV also contribute to
the hurdles faced. Being a retrovirus allows HIV to integrate into the
host cell genome where it can remain latent for many years. The virus
also damages the immune system and changes the dynamics of the
immune environment. This can affect the vaccine's response and dimin-
ish its sustainability (Esparza et al., 2010). A suitable vaccine will there-
fore, need to be one that prevents initial HIV infection (Esparza et al.,
2010).
10.2. Alternative therapeutics
Considering the complex nature of HIV vaccine development and
the issues surrounding ARV toxicity and viral resistance, many re-
searchers are looking at alternative mechanisms of therapy. Since thediscovery of the Δ32 protective effect in HIV, investigators are targeting
the CCR5 receptor at the DNA, transcription and protein levels.
Since the protective effect of Δ32 lies in its ability to induce a trans
dominant negative effect on wild-type CCR5 and CXCR4 protein
expression (Benkirane et al., 1997; Chelli and Alizon, 2001), Luis Abad
et al. used truncated CCR5 molecules to induce a similar effect in
human T-cells (Luis Abad et al., 2003). Upon expression in vitro the
CCR5 truncated molecules signiﬁcantly inhibited CCR5 function and
provided protection against R5 viral strains.
Hutter et al. used anHLAmatched allogeneic stem cell donor to treat
and confer HIV resistance to the patient in their study (Hütter et al.,
2009). The likelihood of ﬁnding anHLAmatchedΔ32 homozygous indi-
vidual to treat each HIV patient is low. Hence the proposal to use autol-
ogous cells that have been genetically engineered to resist HIV by using
gene therapy is a promising avenue (Baltimore, 1988).
RNA interference (RNAi) using small interfering RNAs (siRNAs) or
short hairpin RNA (shRNA) is a mechanism used to target the tran-
scripts of HIV proteins or host cellular components and leads to their
subsequent degradation and a reduction in protein expression
(Novina et al., 2002; Li et al., 2003; Qin et al., 2003; Li et al., 2005; An
et al., 2007; Anderson et al., 2009; Liang et al., 2010).
The study conducted by Anderson et al. used a lentiviral vector
to transduce CCR5+ human cells with a shRNA directed at CCR5
(Anderson et al., 2009). The results of the study illustrated the success-
ful and speciﬁc CCR5 targeting with a 93% reduction in CCR5 expression
and a conferred resistance to HIV. In another study, Liang et al. devel-
oped a novel shRNA to suppress CCR5 in hematopoietic stem cells
(HSCs) (Liang et al., 2010). Results showed that the CCR5 knockdown
cells had a 90% reduction in CCR5 mRNA and were resistant to HIV
infection by R5 strains (Liang et al., 2010). Bifunctional siRNAs were
designed by Ehsani et al. to target the CCR5 co-receptor and HIV RNA
(Ehsani et al., 2010). This ensured that HIV infection and replication
was prevented by using this dual mechanism.
Another mechanism being investigated is zinc ﬁnger nucleases
(ZFNs) which bind to speciﬁc predetermined DNA sequences and
result in a permanent double stranded break resulting from transient
expression of the zinc ﬁnger. Holt et al. demonstrated the success of
ZFN mediated therapy on human HSCs transplanted into NOD/SCID/
IL2rγnull mice. Mice that received ZFN induced cells had lower HIV
levels and showed rapid proliferation of CCR5 null cells as opposed to
untreated mice which had rapid CD4+ T cell decline (Holt et al.,
2010). Other studies have also shown the ability of ZFN-mediated
CCR5 inactivation to confer HIV resistance (Perez et al., 2008).
Gene therapy strategies utilize retroviral or lentiviral vector systems
to transfer the therapeutic product. Both the efﬁciency and success of
such vectors make them popular choices. However, certain risks such
as viral mediated oncogenesis can occur, particularly with the former
(Dropulic, 2005). The Sleeping Beauty Transposon system offers a
non-viral mechanism of gene transfer with investigations showing
stable delivery of siRNAs, efﬁcient knockdown of CCR5 and CXCR4
receptors from the cell surface and successful resistance to HIV viral
strains (Tamhane and Akkina, 2008).
The disadvantages of expressing siRNAs range from off target mRNA
degradation (Jackson et al., 2006) to cytotoxicity (Grimm et al., 2006).
However, clinical trials have thus far demonstrated positive results.
Four patients diagnosed with lymphoma underwent HSC transplanta-
tion with genetically modiﬁed CD34+ cells (DiGiusto et al., 2010). The
cells were transduced with a lentiviral vector containing three RNA
based anti HIV therapeutics one of which was a CCR5 ribozyme. No
changes were observed in hematopoietic potential when compared to
unmodiﬁed cells and there were no related toxicities. The transduced
cells efﬁciently engrafted in all four individuals and showed persistent
expression of the therapeutics 24 months after the transplant. In a
review by Mitsuyasu et al., the authors described two clinical trials
using genetically modiﬁed HSCs which illustrated the safety and feasi-
bility of such a procedure (Mitsuyasu et al., 2011).
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Receptor antagonist drugs are problematic due to drug toxicity and
the emergence of escape mutants. The use of gene therapy on HSCs
may provide a long-term protection against HIV infection and progres-
sion. Transducing HSCs ensures continued self renewal and differentia-
tion potential of HIV resistant cells while ultimately replacing and
reconstituting the individual's HIV depleted immune system as has
been seen with the patient in the Hutter study (Hütter et al., 2009). The
ultimate goal of this therapy is to eliminate the virus completely. The pro-
tocol involved in HSC transplantation includes apheresis of peripheral
blood cells or bone marrow aspiration, isolation of the target cells and
transduction with the vector before subsequent re-administration into
the patient. An eventual protocol should aim to minimize the procedure
by designing a therapeutic vector that only requires direct injection
in vivo where the appropriate cells are then speciﬁcally selected for
transduction.
The notion of eliminating a single receptor as the key to unraveling
the enigma of the HIV cure is still an exciting prospect. However, the
complexities associated with such a task need to be considered. The
idea of CCR5 dispensability is based on the premise that Δ32 homozy-
gous individuals are seemingly healthywith no apparent abnormalities.
However these individuals acquired the mutation through a line of an-
cestry dating back thousands of years. This has allowed these individ-
uals to evolve and possibly adapt to the lack of CCR5 usage by shifting
immune and other functions to alternative receptors or structures. Arti-
ﬁcially inducing a null CCR5 phenotypemay have consequences thatwe
are as yet unaware of. Although the Hutter paper provides a break-
through strategy towards the long awaited cure for HIV (Hütter et al.,
2009), the long-term effect of the treatment on the affected individual
will only be revealed in the next few years.
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